1 |
LU X L, CHEN L L, LI Y, et al. Long non-coding RNA LINC01207 promotes cell proliferation and migration but suppresses apoptosis and autophagy in oral squamous cell carcinoma by the microRNA-1301-3p/lactate dehydrogenase isoform A axis[J]. Bioengineered, 2021, 12(1): 7780-7793.
|
2 |
YAO C, KONG F Z, ZHANG S L, et al. Long non-coding RNA BANCR promotes proliferation and migration in oral squamous cell carcinoma via MAPK signaling pathway[J]. J Oral Pathol Med, 2021, 50(3): 308-315.
|
3 |
CHI A C, DAY T A, NEVILLE B W. Oral cavity and oropharyngeal squamous cell carcinoma: an update[J]. CA Cancer J Clin, 2015, 65(5): 401-421.
|
4 |
SASAHIRA T, KIRITA T. Hallmarks of cancer-related newly prognostic factors of oral squamous cell carcinoma[J]. Int J Mol Sci, 2018, 19(8): 2413.
|
5 |
MODESTO A, SIEGFRIED A, LUSQUE A, et al. Distinct outcomes of oropharyngeal squamous cell carcinoma patients after distant failure according to p16 status: implication in therapeutic options[J]. Curr Oncol, 2021, 28(3): 1673-1680.
|
6 |
ZHONG Q, FANG Y X, LAI Q H, et al. CPEB3 inhibits epithelial-mesenchymal transition by disrupting the crosstalk between colorectal cancer cells and tumor-associated macrophages via IL-6R/STAT3 signaling[J]. J Exp Clin Cancer Res, 2020, 39(1): 132.
|
7 |
LIAO Q, ZENG Z, GUO X, et al. LPLUNC1 suppresses IL-6-induced nasopharyngeal carcinoma cell proliferation via inhibiting the Stat3 activation[J]. Oncogene, 2014, 33(16): 2098-2109.
|
8 |
SULLIVAN N J, SASSER A K, AXEL A E, et al. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells[J]. Oncogene, 2009, 28(33): 2940-2947.
|
9 |
SAITO K, MITSUI A, SUMARDIKA I W, et al. PLOD2-driven IL-6/STAT3 signaling promotes the invasion and metastasis of oral squamous cell carcinoma via activation of integrin β1[J]. Int J Oncol,2021,58(6): 29.
|
10 |
WANG H Y, SI S N, JIANG M J, et al. Leukemia inhibitory factor is involved in the pathogenesis of NSCLC through activation of the STAT3 signaling pathway[J]. Oncol Lett, 2021, 22(3): 663.
|
11 |
NICOLA N A, BABON J J. Leukemia inhibitory factor (LIF)[J]. Cytokine Growth Factor Rev, 2015, 26(5): 533-544.
|
12 |
WYSOCZYNSKI M, MIEKUS K, JANKOWSKI K, et al. Leukemia inhibitory factor: a newly identified metastatic factor in rhabdomyosarcomas[J]. Cancer Res, 2007, 67(5): 2131-2140.
|
13 |
LIU S C, TSANG N M, CHIANG W C, et al. Leukemia inhibitory factor promotes nasopharyngeal carcinoma progression and radioresistance[J]. J Clin Invest, 2013, 123(12): 5269-5283.
|
14 |
YU H Y, YUE X T, ZHAO Y H, et al. LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers[J]. Nat Commun, 2014, 5: 5218.
|
15 |
LIN T A, WU T S, LI Y J, et al. Role and mechanism of LIF in oral squamous cell carcinoma progression[J]. J Clin Med, 2020, 9(2): E295.
|
16 |
WANG W, TAN J Y. Co-inhibition of BET proteins and PD-L1 as a potential therapy for OSCC through synergistic inhibition of FOXM1 and PD-L1 expressions[J].J Oral Pathol Med,2019,48(9):817-825.
|
17 |
李蕴蕴,李瑞喆,秦 慧,等. BAF53a表达对口腔鳞状细胞癌患者预后的影响[J]. 郑州大学学报(医学版), 2020,55(4): 512-515.
|
18 |
NAJAFI M, HASHEMI GORADEL N, FARHOOD B,et al. Macrophage polarity in cancer: a review[J]. J Cell Biochem, 2019, 120(3): 2756-2765.
|
19 |
PETRUZZI M N, CHERUBINI K, SALUM F G,et al.Role of tumour-associated macrophages in oral squamous cells carcinoma progression: an update on current knowledge[J]. Diagn Pathol, 2017, 12(1): 32.
|
20 |
HUANG C M, OU R Z, CHEN X N, et al. Tumor cell-derived SPON2 promotes M2-polarized tumor-associated macrophage infiltration and cancer progression by activating PYK2 in CRC[J]. J Exp Clin Cancer Res, 2021, 40(1): 304.
|
21 |
HUANG T T, SONG C L, ZHENG L, et al. The roles of extracellular vesicles in gastric cancer development, microenvironment, anti-cancer drug resistance, and therapy[J].Mol Cancer,2019,18(1): 62.
|
22 |
LIN Y X, XU J X, LAN H Y. Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications[J]. J Hematol Oncol, 2019, 12(1): 76.
|
23 |
ZHAO X, QI X Q, LIAN W R, et al. Trichomicin suppresses colorectal cancer via comprehensive regulation of IL-6 and TNFα in tumor cells, TAMs, and CAFs[J]. Front Pharmacol, 2020, 11: 386.
|
24 |
GWAK J, JEONG H, LEE K, et al. SFMBT2-mediated infiltration of preadipocytes and TAMs in prostate cancer[J].Cancers (Basel),2020,12(9):E2718.
|
25 |
JIANG W N, BAI W W, LI J H, et al. Leukemia inhibitory factor is a novel biomarker to predict lymph node and distant metastasis in pancreatic cancer[J]. Int J Cancer, 2021, 148(4): 1006-1013.
|
26 |
ZHANG C, LIU J, WANG J M, et al. The emerging role of leukemia inhibitory factor in cancer and therapy[J]. Pharmacol Ther, 2021, 221: 107754.
|
27 |
VAZIRI N, SHARIATI L, JAVANMARD S H. Leukemia inhibitory factor: a main controller of breast cancer[J]. J Biosci, 2020, 45: 143.
|
28 |
WANG D, LIU K, YANG Y C, et al. Prognostic value of leukemia inhibitory factor and its receptor in pancreatic adenocarcinoma[J]. Future Oncol, 2020, 16(3): 4461-4473.
|
29 |
LIU B, LU Y, LI J Z, et al. Leukemia inhibitory factor promotes tumor growth and metastasis in human osteosarcoma via activating STAT3[J]. APMIS, 2015, 123(10): 837-846.
|
30 |
LIU Y N, NIU S X, CHEN W Y, et al. Leukemia inhibitory factor promotes castration-resistant prostate cancer and neuroendocrine differentiation by activated ZBTB46[J]. Clin Cancer Res, 2019, 25(13):4128-4140.
|
31 |
PASCUAL-GARCÍA M, BONFILL-TEIXIDOR E, PLANAS-RIGOL E, et al. LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy[J]. Nat Commun, 2019, 10(1): 2416.
|
32 |
KAMOHARA H, OGAWA M, ISHIKO T, et al. Leukemia inhibitory factor functions as a growth factor in pancreas carcinoma cells: involvement of regulation of LIF and its receptor expression[J]. Int J Oncol, 2007, 30(4): 977-983.
|
33 |
KUPHAL S, WALLNER S, BOSSERHOFF A K. Impact of LIF (leukemia inhibitory factor) expression in malignant melanoma[J]. Exp Mol Pathol, 2013,95(2): 156-165.
|
34 |
LI X Y, YANG Q F, YU H Y, et al. LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway[J]. Oncotarget, 2014, 5(3): 788-801.
|
35 |
WANG J B, XIE C M, PAN S H, et al. N-myc downstream-regulated gene 2 inhibits human cholangiocarcinoma progression and is regulated by leukemia inhibitory factor/microRNA-181c negative feedback pathway[J]. Hepatology, 2016, 64(5): 1606-1622.
|